Treatment Outcomes With tDCS in Post-Stroke Aphasia
Launched by UNIVERSITY OF ARKANSAS · Apr 25, 2019
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people who have difficulty speaking after a stroke, a condition known as post-stroke aphasia. Researchers want to see if combining a special type of brain stimulation called transcranial direct current stimulation (tDCS) with traditional language therapy can help improve speech and language skills more effectively. The study will look at how this treatment works in the brain and if it leads to better recovery outcomes for patients.
To participate in this trial, individuals need to be between 18 and 80 years old, have had a stroke affecting the left side of the brain at least six months ago, and speak English fluently. However, those with severe language comprehension problems, certain neurological conditions, or who are pregnant cannot join. Participants will engage in language therapy sessions supplemented with brain stimulation, and throughout the trial, researchers will monitor their progress and any changes in brain function. This study aims to provide new insights into effective treatments for improving communication abilities after a stroke.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presence of post-stroke aphasia
- • Single left hemisphere stroke etiology
- • At least 6 months post-stroke
- • Age range between 18 and 80 years old
- • Speak English as a native language
- • Adequate hearing and vision to complete the tasks
- Exclusion Criteria:
- • Severe auditory comprehension deficits (determined by pretest) (i.e., global aphasia, Wernicke's aphasia, transcortical sensory aphasia)
- • Inability to provide informed consent
- • Co-occurring history of neurological disease/disorder/injury (e.g., traumatic brain injury, right hemisphere stroke, dementia)
- • Co-occurring history of a major mental illness (e.g., schizophrenia, drug addiction, bipolar)
- • Clinical conditions contraindicated for MRI or tDCS (e.g., implanted electrical devices, claustrophobia, seizure disorder)
- • Positive pregnancy test (for females)
About University Of Arkansas
The University of Arkansas is a leading research institution dedicated to advancing healthcare through innovative clinical trials. With a commitment to excellence in research and education, the university facilitates a collaborative environment that encourages interdisciplinary studies and the development of cutting-edge therapies. Its clinical trial programs leverage state-of-the-art facilities and expert faculty, aiming to improve patient outcomes and contribute to the body of medical knowledge. The university fosters partnerships with healthcare providers and industry stakeholders, ensuring rigorous ethical standards and adherence to regulatory requirements in all research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Little Rock, Arkansas, United States
Patients applied
Trial Officials
Dana Moser, PhD, CCC-SLP
Principal Investigator
University of Arkansas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials